Coronavirus disease-19 and diabetes mellitus: implications for diabetes management in Nigeria

Otovwe Agofure, Anthony Taghogho Eduviere, Oghenenioborue Rume Okandeji-Barry


Coronavirus disease-19 is a viral infection that has spread to the entire regions across the globe. Current evidence shows that diabetes mellitus patients are highly susceptible to severe complications, morbidity and mortality due to this infection. The high susceptibility may be as a result of the associated pathophysiology of coronavirus disease-19 and diabetes mellitus co-morbidity in affected individuals. This narrative review was undertaken to highlight the implications of coronavirus disease-19 infection on diabetes mellitus patients in developing countries with a focus on Nigeria which has a weak health care system and poor clinical patients’ characteristics. A critical literature search was carried out on coronavirus disease-19 and diabetes mellitus. Relevant items were assembled to form the current review on coronavirus disease-19 infections and its implications on diabetes mellitus management in developing countries. The review highlighted the significance of proper glycaemic control as coronavirus disease-19 increases the susceptibility of diabetes mellitus patients to morbidity and mortality which could be overwhelming as the incidence of the infection increases across developing countries like Nigeria.  


Coronavirus disease-19, Diabetes Mellitus, Developing Countries, Nigeria

Full Text:



World Health Organisation. Coronavirus disease (COVID-19) Situation Report– 122. Available at: Accessed on 20 October 2020.

Centre for Disease Control. Novel Coronavirus, Wuhan, China. CDC 2019. Available at 26, 2020; Accessed on 27 January 2020.

Ren LL, Wang YM, Wu ZQ. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J. 2020.

Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respirat Med. 2020.

Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020.

Zhang JJ, Dong X. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.

Bornstein SR, Rubino F, Khunti K. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabet Endocrinol. 2020.

Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395:1225-8.

Ferlita S, Yegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 diabetes mellitus and altered immune system leading to susceptibility to pathogens, especially mycobacterium tuberculosis. J Clinic Medic. 2019;8(12):2219.

Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Experiment Medic. 2005;202(3):415-24.

Wan Y, Shang J, Graham R, Baric RS, Li F. Information: read & look at all below.

Zhou P, Yang X. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020.

Chen Z, McCrosky S. guo W. Li H and gerton JL: A genetic screen to discover pathways affecting cohesin function in Schizosaccharomyces pombe identifies chromatin effectors. g3 (Bethesda). 2012;2:1161-8.

Mehta P, Mcauley D, Brown M. HLH Across Speciality Collaboration, UK. Correspondence COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-4.

Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respirat Medic. 2020.

Hoffmann M, Kleine-Weber H, Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6.

Imai Y, Kuba K, Penninger JM. The discovery of angiotensin converting enzyme-2 and its role in acute lung injury in mice. Exp Physiol. 2008;93:543-8

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Medic. 2005;11(8):875-9.

Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006;6:271-6.

Yajing F, Yuanxiong C, Yuntao W. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virologica Sinica. 2020.

Critchley JA, Carey IM, Harris T. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care, 2018;41:2127-33

Li B, Yang J, Zhao F. Prevalence and impact of cardiovascular, metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020.

Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123:2605-13.

Antoniak S. The coagulation system in host defence. Res Pract Thromb Haemost. 2018;2:549-57.

Miller JL. Blood coagulation and fibrinolysis. In: Henry JB, editor. Clinical Diagnosis and Management by Lab Methods. 17th ed. Philadelphia: WB Saunders, 2001;767-72.

Oudkerk M, Büller HR, Kuijpers D, et al. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands, Radiology. 2020.

Nwose E, Jelinek H, Richards R. D-dimer levels in diabetes. Proceedings of the Australian Health and Medical Research Congress. 2004;232.

Nwose E, Richards R, Jelinek H. D-dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications. Pathology. 2007; 39(2):252-7.

Heit JA, Leibson CL, Ashrani AA. Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism? A Population-Based Case-Control Study. Arterioscler Thromb Vasc Biol. 2009;29(9):1399-405.

Poissy J, Goutay J, Caplan M. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. 2020.

Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Bio Med J. 2003;326:1358-62.

Hwang DM, Chamberlain DW, Poutanen SM, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18:1-10.

Zhang L, Lin D, Sun X. Crystal structure of SARS-CoV-2 main protease provides a basis for the design of improved α-ketoamide inhibitors. Science. 2020;368(6489):409-12.

Ziegler D, Sohr CGH, Nourooz-Zadeh J. Oxidative stress and antioxidant defence in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care. 2004;27:2178-83.

Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metab Clin Exp 2020;107:154217.

Chukwuani U, Yovwin DG, Digban KA. Determinants of glycemic control among persons with type 2 diabetes mellitus in Niger Delta. Sahel Med J. 2016;19(4):190-5.

Unadike BC, Eregie A, Ohwovoriole AE. Glycaemic control amongst persons with diabetes mellitus in Benin City. Nig Med J 2010;51(4):164-6.

Olayemi IA, Osazuwa F. Prevalence of poor glycemic control among Nigerian female diabetics. Niger J Exp Clin Biosci. 2014;2:67-8.

Ndibuagu EO, Arinze-Onyia SU, Chime OH. Knowledge and attitude on diabetes mellitus among residents of a rural community in Enugu State, Southeast, Nigeria. Int Res J Medical Sci. 2016;4:1-7.

Uchenna D, Ambakederemo TE, Jesuorobo DE. Awareness of heart disease prevention among patients attending a specialist clinic in Southern Nigeria. Int J Prevent Treatm. 2012;1:40-3.

Odili VU, Isiboge PD, Eregie A. Patients’ Knowledge of diabetes mellitus in a Nigerian city. Trop J Pham Res. 2011;10:637-42.

Agofure O, Oyewole OE, Igumbor EO. Diabetes care in delta state of Nigeria: An expository review. Diabetes Updates. 2018;1(1):1-8.

Oyewole EO, Agofure O. Patterns of adherence to management among patients with type 2 diabetes mellitus in the South-South Region of Nigeria. J Soc Heal Diabet. 2015;3:115-9.

Fadare J, Olamoyegun M, Gbadegesin BA. Medication adherence and direct treatment cost among diabetes patients attending a tertiary healthcare facility in Ogbomosho, Nigeria. Malawi Med J. 2015;27(2):65-70.

Pascal IG, Ofoedu JN, Uchenna NP. Blood Glucose Control and Medication Adherence Among Adult Type 2 Diabetic Nigerians Attending A Primary Care Clinic in Under-resourced Environment of Eastern Nigeria. N Am J Med Sci. 2012;4(7):310-5.

Adisa R, Fakeye TO. Effect of number and type of antidiabetes medications on adherence and glycemia of ambulatory type 2 diabetes patients in southwestern Nigeria. Pharm Pract (Granada). 2013; 11(3):156-65.

Nwankwo CU, Ezenwaka CE, Onuoha PC, Agbakoba NR. Implementing diabetes self-management education (DSME) in a Nigerian population: perceptions of practice nurses and dieticians. Arch Physiol Biochem. 2015;121:123-7.

Nwose EU, Oguoma VM. Metabolic syndrome and prediabetes in Ndokwa community of Nigeria: preliminary study. N Am J Med Sci. 2015;7:53-8.

Aguocha BU, Ukpabi JO, Onyeonoro UU. Pattern of diabetic mortality in a tertiary health facility in south-eastern Nigeria. Afr J Diab Med. 2013;21:14-6.

Chijioke A, Adamu AN, Makusidi AM. Mortality patterns among type 2 diabetes mellitus patients in Ilorin, Nigeria. J Endocrinol Metabol Diabet South Afr. 2010;15:79-82.

Unadike BC, Essien I, Akpan NA, Peters EJ, Essien OE. Profile and outcome of diabetic admissions at the University of Uyo Teaching Hospital, Uyo. Int J Medic Medical Sci. 2013;5(6):286-9.

Fasanmade OA, Dagogo-Jack S. Diabetes care in Nigeria. Ann Glob Health. 2015;81:821-9.

Awosusi A, Folaranmi T, Yates R. Nigeria’s new government and public financing for universal health coverage. Lancet Global Heal. 2015;3:514-5.

Akande TM. Referral system in Nigeria: Study of a tertiary health facility. Ann Afri Med. 2004;3:130-3.

Otovwe A, Baba A. Knowledge of referral and feedback system among health workers in billiri local government area of Gombe State, Nigeria. Europ J Pharmaceut Medic Res. 2016;3:111-55.